Lamotrigine-induced tic disorder: Report of five pediatric cases

Epilepsia

Volumn 41, Issue 7, 2000, Pages 862-867

  Sotero De Menezes, Márcio Affonseca ^a,b   Rho, Jong M ^a,b   Murphy, Patti ^b   Cheyette, Sarah ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Epilepsy; Lamotrigine; Movement disorder; Side effect; Tic

Indexed keywords

LAMOTRIGINE;

APHASIA; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; LANGUAGE DISABILITY; LARYNGOSCOPY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIC;

EID: 0033922131     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00254.x     Document Type: Article

References (37)

1. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neural 1992;32: 305-7.
2. Uvebrant P, Bauzienè R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure related benefits. Neuropediatrics 1994;25:284-9.
3. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
4. Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995;91:200-2.
5. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
6. Tavernor SJ, Wong IC, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:67-71.
7. Jankovic J. Phenomenology and classification of tics. Neurol Clin North Am 1997;15:267-75.
8. Fawcett J, Bush KA. Stimulants in psychiatry. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacologv, 2nd edition. Washington, DC: The American Psychiatric Press, Inc., 1998:503-22.
9. Kumar R, Lang AE. Tourette syndrome. Secondary tic disorders. Neurol Clin North Am 1997;15:309-31.
10. Lombroso CT. Lamotrigine-induced tourettism. Neurology 1999; 52:1191-4.
11. Lang A. Patient perception of tics and other movement disorders. Neurology 1991;41:223-8.
12. Hogan MB, Wilson NW. Tourette syndrome mimicking asthma. J Asthma 1999;36:253-6.
13. Shapiro AK, Shaprio E, Bruun RD. Gilles de la Tourette syndrome. New York: Raven Press, 1978.
14. Erenberg G, Cruse RP, Rothner AD. Tourette syndrome: an analysis of 200 pediatric and adolescent cases. Cleve Clin Q 1986;53: 127-31.
15. Burd L, Kerbeshian J, Wikenheiser M, Fisher W. A prevalence study of Gilles de la Tourette syndrome in North Dakota school children. Am J Psychiatry 1986;25:552-3.
16. Burd L, Kerbeshian J, Wikenheiser M, Fisher W. Prevalance of Gilles de la Tourette syndrome in North Dakota adults. Am J Psychiatry 1986;143:787-8.
17. Bruun DB, Budman CL. The course and prognosis of Tourette syndrome. Neurol Clin North Am 1997;15:291-8.
18. Neglia JP, Glaze DG, Zion TE. Tics and vocalizations in children treated with carbamazepine. Pediatrics 1984;73:841-4.
19. Burd L, Kerbeshian J, Fisher W, Gascon G. Anticonvulsant medications: an iatrogenic cause of tic disorders. Can J Psychiatry 1986c;31:419-23.
20. Kurlan R, Kersun J, Behr J, Leibovici A, Tariot P, Lichter D, Shoulson I. Carbamazepine-induced tics. Clin Neuropharmacol 1989;12:298-302.
21. Robertson PL, Garofalo EA, Silverstein FS, Komarynski MA. Carbamazepine-induced tics. Epilepsia 1993;34:965-8.
22. Drake ME, Cannon PA. Tourette syndrome precipitated by phenytoin. Clin Pediatr 1985;24:323.
23. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 1999;40:1471-83.
24. Erenberg G. The treatment of Tourrett syndrome with neuroleptic drugs. Neurol Clin North Am 1997;15:241-3.
25. Kurlan R. Treatment of tics. Neurol Clin North Am 1997;15:403-9.
26. Crosley CJ, Swender PT. Dystonia associated with carbamazepine administration: experience with brain damaged children. Pediatrics 1979;63:612-5.
27. Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th edition. New York: Raven Press, 1995:861-9.
28. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7.
29. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-13.
30. Albin RL, Young AB, Penney JP. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75.
31. Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int 1998;33:383-97.
32. Schmidt WJ, Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 1989;32:621-3.
33. Klockgether T, Turki L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine depleted rats. Ann Neurol 1990;28:539-46.
34. Klockgether T, Turki L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT. The AMPA receptor antagonists has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30:717-23.
35. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990;13: 272-6.
36. Zipp F, Baas H, Fischer PA. Lamotrigine-antiparkinsonian activity by blockage of glutamate release? J Neurol Transm 1993;5:67-75.
37. Anderson GM, Pollack ES, Chatterjee JF, Leckman JF, Riddle MA, Cohen DJ. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 1992;58:123-33.